Asteria Health Recalls Testosterone and Anastrozole Sterile Pellets Due to Metal Particulate Matter
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
F.H. INVESTMENTS, Inc. (dba Asteria Health) has issued a voluntary recall for 1,464 units of Testosterone and Anastrozole sterile pellets due to the potential presence of metal particulate matter.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
F.H. INVESTMENTS, Inc. (dba Asteria Health) has initiated a voluntary recall of specific lots of Testosterone 100mg Anastrozole 4mg sterile pellets. The recall was prompted by the discovery of a foreign substance, identified as the potential presence of metal particulate matter within the product.
Which Products Are Affected
The recall involves 1,464 pellets of Testosterone 100mg Anastrozole 4mg (1 Sterile Pellet). The affected products carry the NDC number 79559-4104-32 and are labeled under Asteria Health, Birmingham, AL.
The following lot numbers and expiration dates are included in this recall:
- Lot#: 254000105, Exp. 05/28/2026
- Lot#: 254000110, Exp. 08/07/2026
- Lot#: 254000112, Exp. 09/26/2026
- Lot#: 254000113, Exp. 09/26/2026
What You Should Do
Consumers and healthcare providers should immediately cease use of the affected lots. The firm has initiated notification via letter. For information regarding returns or further instructions, consumers may contact F.H. INVESTMENTS, Inc. (dba Asteria Health) at 432 Industrial Ln, Birmingham, AL 35211-4465.
Why This Matters
The presence of metal particulate matter in a sterile drug product poses a significant health risk, as foreign substances can lead to adverse reactions or complications at the site of administration. This recall is classified as a Class II event by the FDA.
Source
Information provided by the FDA under Recall Number D-0331-2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.